医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GenesisCare Acquires Cancer Partners UK – Cancer Patients to Benefit from Increased Access and New Services

2015年07月02日 AM01:00
このエントリーをはてなブックマークに追加


 

SYDNEY

GenesisCare, Australia’s largest provider of radiotherapy services (GenesisCare), today announced the acquisition of the United Kingdom’s leading provider of private cancer services, Cancer Partners UK (CPUK).

Adding to an existing network of eight cancer treatment centres, GenesisCare has also committed to develop three new treatment centres in areas of need across the UK. A suite of the latest cancer treatment technologies and techniques will also be introduced across all eleven facilities over the next 12 months.

Cancer patients are expected to benefit from continued investment in new personalised treatment techniques such as SABR1, SRS2 and brachytherapy. GenesisCare, with significant experience in providing high quality services in a public hospital tertiary teaching environment across Australia, is also planning to introduce and lead a number of new clinical trials.

Steve Bird, CPUK’s CEO, said “Since our inception, we have been committed to providing precise and sophisticated radiotherapy treatment for cancer patients in the UK and to delivering the best patient care possible. Combining with GenesisCare enables our staff and referring consultants the ability to move forward rapidly to the cutting edge of treatment techniques and provide our patients with even greater choice, opportunity and access to global best practice.”

More than one third of the United Kingdom’s cancer patients who would benefit from radiotherapy are currently not accessing the essential treatment modality at the right time. With CPUK already providing overflow support to National Health Service (NHS) hospitals, it is expected that the GenesisCare linkages will provide even greater support for the NHS as it attempts to meet the rising tide of patient demand.

GenesisCare Managing Director, Dan Collins said “We want all cancer patients to receive the best possible care at the right time. Together with CPUK, GenesisCare is taking on the challenge to provide better outcomes for cancer patients, and to ease the burden across the community. We can achieve a better result for patients across the UK with a focus on innovation, sharing global best practice and investment in the latest technology and treatment techniques. We’re excited at the prospect of making a positive difference.”

Dr Michael Guiney, GenesisCare Radiation Oncologist and Director on the GenesisCare Board said “This is a very exciting time for GenesisCare but also for the practice of radiotherapy and cancer care globally. To be in a position to share best practice across borders and cultures and transcend the silos of healthcare that naturally exist in regulated environments is truly unique. As a practising Oncologist, it is a fantastic journey to be on and I look forward to what this partnership will deliver for patients.”

GenesisCare recently announced a partnership with Ramsay Health Care for the development of two new sites at the Rivers Hospital in Sawbridgeworth and the Springfield Hospital in Chelmsford. With these two comprehensive cancer services opening in early 2016 and CPUK’s ninth site commencing in Kent in December 2015, the combined GenesisCare UK network will be eleven sites. In Australia, GenesisCare operates more than twenty five cancer treatment centres.

1 Stereotactic Ablative Radiotherapy (SABR)
2 Stereotactic Radio Surgery

Notes to Editors

About CPUK (www.cancerpartnersuk.org)

Cancer Partners UK provides the highest levels of patient-focused care across a network of eight purpose-built cancer treatment centres. CPUK employs over 160 staff with a referral network of over 100 consultant oncologists.

Each centre has been individually designed to meet the needs of the local area but each aspires to provide the same high standard of patient services. Daily image guided radiotherapy and intensity modulated radiotherapy are at the core of each centre, along with volumetric arc therapy and, other specialist treatment techniques including deep inspiration breath-hold to help minimise any side effects for patients with certain types of cancers.

The radiotherapy centres are located in partnership with leading private hospitals, and are in Birmingham, Elstree, Guildford, Nottingham, Portsmouth and Southampton.

Two comprehensive outpatient diagnostic treatment centres – located in Milton Keynes (Linford Wood Medical Centre) and Oxford (Sandford Medical Centre) – additionally provide outpatient services – diagnostic tests and consultations and chemotherapy services. A third treatment centre in King’s Hill, Kent (West Malling Diagnostic and Treatment Centre) is due to open in December 2015. A joint venture with Penny Brohn Cancer Care (http://www.pennybrohncancercare.org/) means that patients are provided with access to holistic care through ‘a Living Well’ programme to further compliment their service experience and improve their care needs.

About GenesisCare (www.genesiscare.com.au)

GenesisCare provides high quality specialist care to patients with cancer and cardiovascular disease, the two largest disease burdens globally. The organisation exists to improve quality and access for patients and communities in need. The Group is the largest provider of radiotherapy across Australia, operating 25 cancer centres in major metropolitan and also regional settings (including in tertiary teaching public hospitals). More than 80 locations provide cardiology and sleep services. GenesisCare employs more than 1500 highly trained health professionals and support staff including more than 150 physicians and leads or participates in more than 110 clinical trials.

Cancer care is provided for all tumour groups with the latest techniques including intensity modulated radiotherapy, volumetric arc therapy, stereotactic radiotherapy and radiosurgery, low dose rate and high dose rate brachytherapy.

The GenesisCare medical team comprises some of the world’s most experienced specialists with many dedicating time as consultants in public hospitals or participating in research and teaching. GenesisCare is adopting internationally proven medical technologies integrated with electronic healthcare records to improve patient clinical outcomes and their service experience.

Radiotherapy

Radiotherapy is a highly cost effective and clinically effective treatment for cancer. It accounts for just 5% of the national spend on cancer treatment in the UK and yet is the second most effective treatment for cancer (next to surgery). Of all patients cured of their cancer, 40% will have received radiotherapy as part of their curative treatment and 16% of all cures can be attributed entirely to their radiotherapy.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701005820/en/

CONTACT

For further information please contact:
Canning Corporate
Communication
Nigel Kassulke
Partner
T: +61 2 8284 9990
M:
+61 407 904 874
E: nkassulke@cannings.net.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表